Invasive Fungal Infections in High-Risk Patients: Report from TIMM-8 2017

Abstract

Trends in Medical Mycology (TIMM) is the biennial meeting of the Infectious Disease Group of the European Organisation for Research and Treatment of Cancer (EORTC) and the European Confederation of Medical Mycology (ECMM). It brings together clinicians and researchers from across the world to share the latest R&Ds in medical mycology. Despite advances in treatment, invasive fungal infections remain a major cause of morbidity and mortality in certain high-risk groups of patients, particularly in immunocompromised patients, including those undergoing solid organ transplantation and those with acute leukemia. The challenges for clinicians are now compounded by the rapid development of multidrug resistance. The latest data and approaches to identifying patients at high risk for invasive fungal infections, ensuring early diagnosis and achieving effective treatment, including when and how to use therapeutic drug monitoring with azoles, were shared with >1000 clinicians and researchers from around the world attending the eighth TIMM, held in Belgrade, Serbia, in October 2017 (TIMM-8 2017).

Keywords::

• antifungal resistance
• azole drug monitoring
• invasive fungal infections
• prophylaxis

Financial & competing interests disclosure

L Pagano participated as a speaker at the MSD symposium held at TIMM-8.  He is an advisory board member and speaker for Gilead, Cidara, MSD, and Pfizer. S Mayor's attendance at TIMM-8 and her contribution to the writing of the report were supported by MSD. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript, and the funding source was MSD.